What does CD3 Labs do?

CD3 Labs is a research organisation in Leuven. Non-profit, started on 30 March 2007, 1 establishment.

What is the address of CD3 Labs?

The registered office of CD3 Labs is located at Gaston Geenslaan 2, 3001 Leuven.

Is CD3 Labs still active?

Yes. According to the CBE (29 October 2026) CD3 Labs is active, legal situation “Normale toestand”, started on 30 March 2007.

Is CD3 Labs registered on Peppol?

Yes, CD3 Labs is registered on the Peppol network with ID 0208:0888594828.

What is the enterprise number of CD3 Labs?

The enterprise number of CD3 Labs is BE0888594828.

When was CD3 Labs founded?

CD3 Labs was founded on 30 March 2007.

Who are the directors of CD3 Labs?

According to the 2025 annual accounts, the directors of CD3 Labs are: Paul Van Dun , Patrick Chaltin, Yves Vertenten.

Is CD3 Labs a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 March 2007; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did CD3 Labs make in 2025?

CD3 Labs recorded a loss after taxes of € 118,898 in financial year 2025.

What is the revenue of CD3 Labs?

In its most recent annual accounts (2025), CD3 Labs reported revenue of € 9,997,131.

How much does an employee at CD3 Labs earn?

The average wage cost per full-time employee at CD3 Labs was € 137,000 in 2025: staff costs of € 6 million for 43.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CD3 Labs have?

According to the 2025 annual accounts, CD3 Labs has 43.5 full-time equivalents (FTE).

Does CD3 Labs have a website?

Yes, CD3 Labs has a website at cistim.be.

CD3 Labs (Non-profit) - Leuven - BE0888594828

Dossier CD3 Labs, printed on 29 October 2026 from databakkes.be/en/0888594828/cd3-labs. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CD3 Labs from Leuven, company number BE0888594828, closed financial year 2025 with a result of € -118,898 after tax. For that financial year CD3 Labs recorded revenue of € 10 million and equity of € 21,267. Compared with financial year 2024, the result moved from € 98,510 to € -118,898. The company made a loss. The buffer shrank hard: equity is 85 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.

What it is worth Shrank hard

€ 21,267

▼ 85% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -118,898

▼ still € 98,510 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 286,100

▼ 47% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Full-time equivalents

43.5

▲ 0.8 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 6 million

▲ 15% vs 2024

€ 137,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 858,695

▲ 54% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 904,045

▼ 3% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 9,693,178 Revenue 2022: € 9,693,178 First fiscal year in the series	€ 10,640,413 Revenue 2023: € 10,640,413 ▲ 10% vs 2022 (€ 9,693,178) Favourable step	€ 11,076,821 Revenue 2024: € 11,076,821 ▲ 4% vs 2023 (€ 10,640,413) Favourable step	€ 9,997,131 Revenue 2025: € 9,997,131 ▼ 10% vs 2024 (€ 11,076,821) Unfavourable step	▼ 10%
Gross margin	€ 4,532,292 Gross margin 2022: € 4,532,292 First fiscal year in the series	€ 5,000,925 Gross margin 2023: € 5,000,925 ▲ 10% vs 2022 (€ 4,532,292) Favourable step	€ 5,341,072 Gross margin 2024: € 5,341,072 ▲ 7% vs 2023 (€ 5,000,925) Favourable step	€ 5,851,148 Gross margin 2025: € 5,851,148 ▲ 10% vs 2024 (€ 5,341,072) Favourable step	▲ 10%
Profit after taxes	€ -107,192 Profit after taxes 2022: € -107,192 First fiscal year in the series	€ 16,950 Profit after taxes 2023: € 16,950 ▲ € 124,142 vs 2022 (€ -107,192) Favourable step	€ 98,510 Profit after taxes 2024: € 98,510 ▲ € 81,560 vs 2023 (€ 16,950) Favourable step	€ -118,898 Profit after taxes 2025: € -118,898 ▼ € 217,408 vs 2024 (€ 98,510) Unfavourable step	▼ € 217,408
Equity	€ 24,705 Equity 2022: € 24,705 First fiscal year in the series	€ 41,655 Equity 2023: € 41,655 ▲ 69% vs 2022 (€ 24,705) Favourable step	€ 140,165 Equity 2024: € 140,165 ▲ 236% vs 2023 (€ 41,655) Favourable step	€ 21,267 Equity 2025: € 21,267 ▼ 85% vs 2024 (€ 140,165) Unfavourable step	▼ 85%
Total debts	€ 1,719,958 Total debts 2022: € 1,719,958 First fiscal year in the series	€ 1,648,327 Total debts 2023: € 1,648,327 ▼ 4% vs 2022 (€ 1,719,958) Favourable step	€ 1,490,791 Total debts 2024: € 1,490,791 ▼ 10% vs 2023 (€ 1,648,327) Favourable step	€ 1,765,457 Total debts 2025: € 1,765,457 ▲ 18% vs 2024 (€ 1,490,791) Unfavourable step	▲ 18%
Cash	€ 113,169 Cash 2022: € 113,169 First fiscal year in the series	€ 345,847 Cash 2023: € 345,847 ▲ 206% vs 2022 (€ 113,169) Favourable step	€ 536,954 Cash 2024: € 536,954 ▲ 55% vs 2023 (€ 345,847) Favourable step	€ 286,100 Cash 2025: € 286,100 ▼ 47% vs 2024 (€ 536,954) Unfavourable step	▼ 47%
Land & buildings	€ 135,553 Land & buildings 2022: € 135,553 First fiscal year in the series	€ 114,399 Land & buildings 2023: € 114,399 ▼ 16% vs 2022 (€ 135,553) Unchanged	€ 93,620 Land & buildings 2024: € 93,620 ▼ 18% vs 2023 (€ 114,399) Unchanged	€ 72,841 Land & buildings 2025: € 72,841 ▼ 22% vs 2024 (€ 93,620) Unchanged	▼ 22%
Retained profit	€ 24,705 Retained profit 2022: € 24,705 First fiscal year in the series	€ 41,655 Retained profit 2023: € 41,655 ▲ 69% vs 2022 (€ 24,705) Favourable step	€ 140,165 Retained profit 2024: € 140,165 ▲ 236% vs 2023 (€ 41,655) Favourable step	€ 21,267 Retained profit 2025: € 21,267 ▼ 85% vs 2024 (€ 140,165) Unfavourable step	▼ 85%
Balance sheet total	€ 1,744,664 Balance sheet total 2022: € 1,744,664 First fiscal year in the series	€ 1,689,982 Balance sheet total 2023: € 1,689,982 ▼ 3% vs 2022 (€ 1,744,664) Unchanged	€ 1,630,956 Balance sheet total 2024: € 1,630,956 ▼ 3% vs 2023 (€ 1,689,982) Unchanged	€ 1,786,723 Balance sheet total 2025: € 1,786,723 ▲ 10% vs 2024 (€ 1,630,956) Unchanged	▲ 10%
Employees (FTE)	38.8 Employees (FTE) 2022: 38.8 First fiscal year in the series	43 Employees (FTE) 2023: 43 ▲ 4.2 vs 2022 (38.8) Unchanged	42.7 Employees (FTE) 2024: 42.7 ▼ 0.3 vs 2023 (43) Unchanged	43.5 Employees (FTE) 2025: 43.5 ▲ 0.8 vs 2024 (42.7) Unchanged	▲ 0.8

Key figures of CD3 Labs, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CD3 Labs?

What happened at CD3 Labs in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 19, 2026 New annual accounts for financial year 2025: loss of € 118,898 (▼ € 217,408 vs 2024). Source: NBB ↗
Jul 12, 2007 New establishment in Leuven. KBO
Mar 30, 2007 Start of the company according to the CBE. KBO

In short

From € 107,192 loss in 2022 to € 118,898 loss in 2025.

Paid € 5,918 in corporate taxes since 2022.

Best year ever: 2024, with € 98,510 profit.

On average € 134,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Paul Van Dun Patrick Chaltin Yves Vertenten

Regionaal Ziekenhuis Heilig Hart Tienen

reMYND

VersaSense

CD3 Labs

Behind CD3 Labs are Paul Van Dun , Patrick Chaltin and Yves Vertenten. Paul Van Dun is also behind Regionaal Ziekenhuis Heilig Hart Tienen, reMYND, VersaSense, Zeopore Technologies and Wetenschapspark Leuven Noord.

Directors

According to the 2025 annual accounts

Paul Van Dun

Director

Also active at: Regionaal Ziekenhuis Heilig Hart Tienen, reMYND, VersaSense, Zeopore Technologies, Wetenschapspark Leuven Noord, PARKEERGEBOUW, Community Building Arenberg

Patrick Chaltin

Director

Yves Vertenten

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Gaston Geenslaan 2

3001 Leuven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

Antleron

€ 1.6 million gross margin · 2025

ALIGOS BELGIUM

€ 3.2 million gross margin · 2025

Bar.on

€ -66,328 gross margin · 2024

Skylight Therapeutics

Stichting Administratiekantoor Bar.on

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS cistim.be

Canonical: https://www.cistim.be/

Technologies

Adobe FontsApacheCraft CMSGoogle FontsGoogle Tag ManagerPWAjQuery

Hosting & Email

Email provider

Self-hosted

Hosting

BELNET, BE

Website info

HTTPS Ja

Languages EN

Features

Ads

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ IPv6

Details

Company number

0888.594.828

VAT number

BE 0888.594.828

Registered office

Gaston Geenslaan 2, 3001 Leuven

Names & denominations

CD3 Labs

Enterprise type

Rechtspersoon

Legal form

Non-profit association

Legal situation

Normale toestand

Start date

30 March 2007

Peppol

Active · Active since 4 Dec 2025

Contact

cistim.be

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

CD3 Labs

Financials

What happened to CD3 Labs?

Management

Directors

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions